Two enzyme defects in purine metabolism are associated with severe primary immunodeficiency. Adenosine deaminase (ADA) deficiency occurs in some cases of autosomal recessive severe combined immunodeficiency of infancy. ADA (EC3.5.4.4) deaminates adenosine to form inosine but adenosine itself does not accumulate in ADA-deficient lymphocytes. This is presumably because the adenosine is converted to adenosine monophosphate (AMP) by adenosine kinase (Figure I) , which in turn leads to increased adenosine triphosphate (ATP) production. High levels of ATP are found in unstimulated lymphocytes from such patients, although it is not clear precisely how this inhibits cellular proliferation. The major biochemical defect is now thought to be caused by the high concentrations of circulating deoxyadenosine found in this condition. This is selectively 'trapped' by lymphocytes and converted to deoxyadenosine triphosphate which is lymphotoxic (Carson et al. 1977) . ADA is found in most tissues but it is convenient to screen patients for the defect by assaying the activity in red blood cells. Prenatal diagnosis is also possible by measuring the activity in amniotic fluid cells obtained at amniocentesis. A potentially major therapeutic advance was made when Polmar et al. (1976) found that red cell transfusions from a normal donor improved immunocompetence in one patient with ADA deficiency and severe combined immunodeficiency. This should encourage researchers in this field to consider enzyme replacement therapy for other lymphocyte enzyme defects. There is an excellent review of this condition by Polmar (1977) . Four patients have been described with purine nucleoside phosphorylase (PNP, EC 2.4.2.1) deficiency which is the enzyme that converts inosine or guanosine to hypoxanthine or guanine (Giblett et al. 1975 , Cohen et al. 1976 , Stoop et al. 1977 . These children are capable of producing antibodies but have a lymphopenia, very low numbers of circulating T lymphocytes and have absent delayed hypersensitivity skin tests. Although they have all suffered from recurrent bacterial and viral infections, other features have differed in that one had a severe anaemia and another suffered from spastic tetraparesis. The reason why this enzyme defect selectively affects T lymphocytes is not known.
About two years ago we were investigating solubilized fractions of lymphocyte plasma membranes from patients with primary hypogammaglobulinaemia. The enzyme, 5'-nucleotidase, was used as a plasma membrane marker in these studies and was found to be greatly reduced in the patients' cells (Johnson et al. 1977) .Since then we have investigated this enzyme in a larger number of patients with various types of immunodeficiency disease and have also attempted to find a physiological role for the enzyme (Webster et al. 1978) . However, before describing this work it is appropriate to briefly outline the present knowledge on purine metabolism in lymphocytes.
Lymphocyte purine metabolism
Research on purine metabolism in human tissues has only relatively recently been extended to the study of lymphocytes. Much of the understanding of the relevance of certain metabolic pathways has evolved from studying rare inherited enzyme defects. For example, patients with the Lesch Nyhan syndrome have very low or absent levels of hypoxanthine guanine phosphoribosyl transferase (HGPRT, EC 2.4.2.8) which is one of the enzymes involved in salvaging purine bases for reutilization ( Figure I ). Patients with this defect develop severe mental retardation underlying the importance of salvage pathways in neuronal metabolism. Our own work has shown that these patients have a subtle and clinically insignificant defect in immunity manifested by low serum IgG levels and low isohaemagglutinin titres (Allison et al. 1975) . In vitro lymphocyte transformation with phytohaemagglutinin is normal in these patients, supporting the view that the de novo pathway for purine synthesis is important for lymphocyte proliferation. Very little is known about the relevance of purine interconversion pathways although these are clearly important, as shown by the defects associated with ADA and nucleoside phosphorylase deficiency. The pathways involving 5'-nucleotidase in Figure I are provisional since very little enzyme activity is found inside the cell (see below).
Lymphocyte 5'-nucleotidase Methods ofmeasurement and site ofenzyme activity 5 '-nucleotidase is found in the cells of many tissues and hydrolyses 5 /-mononucleotides (e.g. 5 /-AMP) to the corresponding nucleoside with the release of inorganic, phosphate. Most of the work on the enzyme has been on liver cells where, in mice, it is a glycoprotein (Evans & Gurd 1973) with the active site on the outer surface of the plasma membrane (Uusitalo & Karnovsky 1977) . Quagliata et al. (1974) and more recently ourselves, have shown that the enzyme is also located on the outer surface of human lymphocyte plasma membranes. The evidence that 5 /nucleotidase is an 'ectoenzyme' is based on the finding that the activity can be measured in intact cells, is'not increased following cellular disruption, and can be inhibited by agents such as concanavalin A which bind to the cell surface.
The enzyme activity is measured in intact mononuclear cells obtained from defibrinated venous blood following separation on a Ficoll/Triosil density gradient. Quantitative assays are performed using the method of Shenoy & Clifford (1975) . In brief, this involves adding radiolabelled [8_ 14 C] 5 '-adenosine monophosphate to lymphocytes as substrate, incubating at 37°C for 10 minutes' and separating the product, adenosine, in the supernatant using high voltage electrophoresis. The radio-labelled adenosine is then located by its ability to fluoresce in ultraviolet light and counted under scintillation fluid. Histochemical techniques are also available where cytocentrifuge preparations of cells are made and incubated with 5'-AMP (Silber et al. 1975) . Phosphate released at the cell surface is then precipitated to lead phosphate by adding lead nitrate. Ammonium sulphide is finally added to produce lead sulphide which is visible as a black precipitate. This technique is relatively insensitive and only seems to stain cells with high activity. Figure 2 shows the results of 5'-nucleotidase activity in patients with 'common variable' hypogammaglobulinaemia, patients with X-linked hypogammaglobulinaemia and 3 cases of selective IgA deficiency. The majority of patients with 'common variable' hypo gammaglobulinaemia have very low levels of lymphocyte 5'-nucleotidase in contrast to patients with X-linked hypogammaglobulinaemia whose levels fall within the normal range. There is also a striking difference when the histochemical technique is used (Figure 3) . However, it is of interest that the levels in the X-linked group fall at the lower end of the normal range. Provisional findings in our laboratory indicate that B lymphocytes have much more activity than T cells and this may explain the 'low normal' levels found in the X-linked group who lack B cells (Rowe et al. 1979) .The unexpected finding of low levels in the patients with selective IgA deficiency provides a link between this disease and severe panhypogammaglobulinaemia. This link can also be observed at a clinical level where, in our series, there is an increased incidence of selective IgA deficiency in family members of patients with 'common variable' hypogammaglobulinaemia.
Characterization and physiological role oflymphocyte 5'-nucleotidase Studies using inhibitors of alkaline and acid phosphatase (fJ glycerophosphate, sodium potassium tartrate) and 5'-nucleotidase (thymidine triphosphate (TTP) or ATP), in addition to using alternative substrates such as 2'-or 3'-AMP, show that the activity we are measuring is in fact due to 5'-nucleotidase (Webster et al. 1978) . Substrate specificities show that the enzyme is active against a wide variety of mononucleotides, being particularly active against AMP, uridine monophosphate (UMP), inosine monophosphate (IMP) and guanosine monophosphate (GMP). The available evidence suggests that liver cell 5'-nucleotidase plays a part in the transport of purines from the liver cell to red cells (M urray 1971) . A similar function might be beneficial for rapidly-dividing lymphocytes as a method of acquiring additional purines from extracellular sources. Nucleosides (e.g. inosine) enter cells by specific transport mechanisms, but mononucleotides (e.g. IMP) are excluded (Berlin & Oliver 1975) . Inosine and IMP do enhance H 3 thymidine uptake in phytohaemagglutinin (PHA) stimulated cultures from normal subjects, the latter presumably entering the cell as inosine having been hydrolysed by 5'-nucleotidase on the lymphocyte surface. 5'-nucleotidase might therefore provide nucleosides such as inosine which could theoretically bypass de novo synthesis. This would be useful when de novo synthesis is compromised -a situation which may occur when lymphocyte proliferation takes place in anaerobic conditions. However, it was found that neither inosine nor IMP was capable of preventing inhibition of DNA synthesis caused by azaserine (Matamoros & Webster, unpublished), a glutamine analogue which blocks de novo synthesis (Henderson & Paterson 1973) . These experiments suggest that lymphocyte 5 ' -nucleotidase plays little part in providing purine nucleosides from extracellular sources of mononucleotides. It is also unlikely that mononuc1eotides exist in significant concentrations in the extracellular environment. Furthermore, the need for additional purines by dividing lymphocytes should be satisfied by hypoxanthine which produces a similar enhancement of DNA synthesis to inosine. Measurable quantities of hypoxanthine do occur in plasma and it is ,also the predominant purine present in transfer factor prepared from disrupted lymphocytes (Odorisio et al. 1976) . A more attractive role for lymphocyte 5'-nucleotidase, particularly since the enzyme is on the cell .surface, is that it is involved in cell collaboration by providing nucleosides which act as messenger molecules.
It is unlikely that the lymphocyte 5'-nucleotidase deficiency found in patients with 'common variable' hypogammaglobulinaemia and selective IgA deficiency is the underlying cause of their disease. It probably reflects a defect in lymphocyte maturation, since 5 ' -nucleotidase activity has been shown to change during the different stages of chick cartilage cell maturation (Rodan et al. 1977) . The virtually absent levels of enzyme activity in many of the patients with 'common variable' hypogammaglobulinaemia indicates the presence of both a T and B lymphocyte disorder.
